About us

Purpose Pharma is a European based pharmaceutical company focusing on the development and commercialization of innovative rare disease and specialty care products in areas of high unmet medical need.

Recent news

Purpose Pharma launches ATTROGY® (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis in Germany

Stockholm, November 17, 2025 – Purpose Pharma International AB today announced that ATTROGY® (diflunisal) is now available in Germany for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in adult patients

Purpose Pharma receives European Commission approval of ATTROGY® (diflunisal) for the treatment of hereditary  transthyretin-mediated amyloidosis

Stockholm, July 31, 2025 – Purpose Pharma International AB today announced that the European Commission (EC) has granted ATTROGY® (diflunisal) marketing authorization for the treatment of hereditary transthyretin-mediated (hATTR or

Purpose Pharma receives positive CHMP opinion for Attrogy® (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis

Stockholm, April 28, 2025 – Purpose Pharma International AB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a

People

Purpose

Products

Purpose

Our purpose is to help people with rare diseases live a better life. Through our own products and by supplying the healthcare system with unlicensed medicines, we provide treatments that make a change with the aim to improve the lives of patients and their families.

What we do

We invest in the development of products to help people with rare diseases live a better life.

On a mission to give people with rare diseases a better life.

Address

Purpose Pharma International AB
Grev Turegatan 13b
114 46 Stockholm Sweden